Last updated: February 13, 2026
Overview
NDC 00088-2220 is marketed as Erythropoietin Alfa, a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease (CKD), chemotherapy, and other causes. The drug is supplied under various brand names, including Epogen and Procrit, and is produced by Amgen.
Market Size and Demand Drivers
- Global Incidence of Anemia: Approximately 400 million people affected globally; demand driven primarily by CKD and cancer patients.
- U.S. Market Composition: Estimated at $2.3 billion in 2022, with Erythropoietin Alfa accounting for roughly 70-80% of demand.
- Growth Factors:
- Increasing CKD prevalence driven by diabetes and hypertension.
- Aging populations in developed markets.
- Advances in supportive care protocols.
Market Competitors
- Biosimilars: Multiple biosimilars have entered markets in Europe, Asia, and the US since FDA approvals began in 2018.
- Key Biosimilar Players: Pfizer (Retacrit), Hospira (Sandoz), and Amgen’s own biosimilar variants.
- Market Share Trends: Biosimilars capturing 25-35% of the US market as of 2022, with continued growth expected.
Pricing Landscape
| Drug |
Dosage Form |
Approximate US Price (per dose) |
Market Notes |
| Epogen / Procrit (Brand) |
Varies |
$300–$400 |
Premium priced, used in hospitals and clinics |
| Retacrit (biosimilar) |
Varies |
$150–$200 |
Gaining market share, offered at a discount |
| Other biosimilars |
Varies |
$140–$190 |
Competing on price, limited switching barriers |
Historical Price Trends
- Brand prices have remained relatively stable but have seen slight discounts for institutional bulk purchasing.
- Biosimilars have reduced average prices by 40–50% relative to brand names in markets where they are adopted.
Price Projections (Next 5 Years)
- Base Case: Moderate biosimilar uptake and stable demand will keep prices for branded erythropoietin stable at $300–$400 per dose.
- Optimistic Scenario: Increased biosimilar penetration could reduce brand prices by an additional 20–30%, with biosimilar prices falling below $150 per dose.
- Downside Scenario: Supply chain disruptions or regulatory hurdles may slow biosimilar adoption, keeping prices close to current levels.
| Year |
Estimated Average Price (per dose) |
Remarks |
| 2023 |
$330 |
Steady brand prices; biosimilar share rising |
| 2025 |
$300 |
Biosimilar market share exceeds 50% in some regions |
| 2027 |
$250 |
Biosimilars reach majority market share; branded prices decline further |
Regulatory and Reimbursement Influences
- FDA Approvals: Biosimilar approvals since 2018 facilitate price competition; more biosimilars likely in pipeline.
- Reimbursement policies: CMS and private insurers increasingly favor biosimilars, incentivizing switching.
- Pricing regulations: Pricing caps in certain European countries influence global pricing trends.
Key Market Trends
- Biosimilars are expected to account for 50% of the erythropoietin market in the US by 2027.
- Adoption of biosimilars leads to a 30–40% price reduction for the same doses.
- The overall global erythropoietin market is projected to grow at a CAGR of 4–5% through 2030.
Conclusion
The current market for NDC 00088-2220 (Erythropoietin Alfa) faces downward pressure on pricing due to biosimilar competition. Price stabilization for branded products persists in the short term, but broad biosimilar adoption is likely to reduce average prices long-term.
Key Takeaways
- The US erythropoietin market was valued at approximately $2.3 billion in 2022.
- Biosimilars are beginning to influence pricing, with potential price reductions of up to 50% by 2027.
- Drivers include rising CKD prevalence, aging populations, and supportive regulatory environments.
- Market share shifts are accelerating in favor of biosimilars, which may dominate the market within five years.
- Price projections suggest stabilization around $300 per dose for brand drugs, with biosimilars trending below $150.
FAQs
-
What are the primary indications for NDC 00088-2220?
Anemia related to chronic kidney disease, chemotherapy, and certain other medical conditions.
-
How is biosimilar entry affecting the market?
Biosimilars are gaining market share rapidly, leading to significant price competition and potential reductions of 30–50% in drug prices.
-
What factors influence future pricing trends?
Regulatory approvals, reimbursement policies, biosimilar adoption rates, and manufacturing costs.
-
Are there regional differences in market dynamics?
Yes; the US market is the most mature, with significant biosimilar penetration, whereas markets in Europe and Asia are at different adoption stages.
-
What is the outlook for upcoming biosimilar approvals?
Several biosimilar candidates are in late-stage development, which will likely intensify competition post-approval.
Sources
- IQVIA. (2022). US Market Data on Erythropoietin.
- FDA. (2018-2022). Biosimilar Approval Announcements.
- EvaluatePharma. (2022). Global Market Forecasts.
- CMS. (2022). Reimbursement Policies for Biosimilars.
- GoodRx. (2022). Price Data for Erythropoietin Alfa.
